RMD · Resmed Inc

$240.98 +0.65 (+0.27%)

S&P 500 member Russell 1000 member Rebalance outlook locked

Market Cap

$34.67B

144.25M

Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.

Revenue

$5.65B +9.9%

FY2026

Net Income

$1.52B +8.8%

FY2026

Gross Margin

61.06% +1.7pp

FY2026

Operating Margin

33.37% +0.6pp

FY2026

Diluted EPS

$10.43 +9.7%

FY2026

Operating Cash Flow

$1.81B +3.1%

FY2026

Chart any reported metric, KPI or segment over time — the full statement history lives here

Income Statement Balance Sheet Cash Flow Adjusted All Metrics

Annual Quarterly

Line Item	3Y	5Y	10Y	FY2027 (G)	TTM	FY2026	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020	FY2019	FY2018	FY2017	FY2016	FY2015	FY2014	FY2013	FY2012	FY2011	FY2010	FY2009
Revenue	+10.2%	+12.1%	+11.9%	$5.75B – $5.85B	—	$5.65B	$5.15B	$4.69B	$4.22B	$3.58B	$3.2B	$2.96B	$2.61B	$2.34B	$2.07B	$1.84B	$1.68B	$1.55B	$1.51B	$1.37B	$1.24B	$1.09B	$920.74M
Net Interest Income	—	—	—	—	-$54.73M	—	—	—	-$47.38M	-$22.31M	-$23.63M	-$39.36M	—	—	—	—	—	—	—	—	—	—	—
Rental Income	—	—	—	—	—	—	—	—	—	$90.08M	$93.43M	$87.87M	—	—	—	—	—	—	—	—	—	—	—
Cost of Revenue	+5.6%	+10.2%	+11.0%	—	—	$2.2B	$2.09B	$2.03B	$1.87B	$1.55B	$1.36B	$1.24B	$1.11B	$1.01B	$864.99M	$772.22M	$667.52M	$565.19M	$573.8M	$547.78M	$501.82M	$436.87M	$366.93M
Gross Profit	+13.6%	+13.4%	+12.5%	—	—	$3.45B	$3.05B	$2.66B	$2.36B	$2.02B	$1.84B	$1.72B	$1.49B	$1.33B	$1.2B	$1.07B	$1.01B	$989.79M	$940.66M	$820.74M	$741.33M	$655.48M	$553.8M
Gross Margin	—	—	—	—	—	61.06%	59.36%	56.67%	55.78%	56.57%	57.53%	58.09%	57.32%	57.04%	58.15%	58%	60.24%	63.65%	62.11%	59.97%	59.63%	60.01%	60.15%
Research & Development	+9.6%	+10.9%	+12.3%	—	—	$378.29M	$331.28M	$307.53M	$287.64M	$253.58M	$225.28M	$201.95M	$180.65M	$155.15M	$144.47M	$118.65M	$114.87M	$118.23M	$120.12M	$109.73M	$92.01M	$75.2M	$63.06M
Selling, General & Administrative	+8.6%	+10.8%	+8.7%	—	—	$1.12B	$993.05M	$917.14M	$874M	$737.51M	$670.39M	$676.69M	$645.01M	$600.37M	$553.97M	$488.06M	$478.63M	$450.41M	$430.8M	$402.62M	$372.25M	$328.86M	$289.88M
Amortization of Intangibles	+1.5%	-6.8%	+0.5%	—	—	$31.78M	$32.12M	$32.96M	$30.4M	$39.65M	$45.13M	$49.6M	$42.51M	$27.27M	$46.6M	$30.2M	$15M	$15.9M	$17M	$13.97M	$10.15M	$8.04M	$7.06M
Depreciation & Amortization	+6.8%	+5.1%	+8.8%	—	—	$201.34M	$198.47M	$176.87M	$165.16M	$159.61M	$156.76M	$154.85M	$150.8M	$119.96M	$112.16M	$86.85M	$73.06M	$73.45M	$78.28M	$85.86M	$70.62M	$61.56M	$53.96M
Restructuring Charges	+33.3%	+20.2%	+12.1%	—	—	$21.75M	$0	$64.23M	$9.18M	$0	$8.67M	$0	$9.4M	$18.43M	$12.36M	$6.91M	—	$6.33M	—	—	—	—	—
Total Operating Expenses	+8.5%	+10.8%	+9.4%	—	—	$1.57B	$1.37B	$1.34B	$1.22B	$1.02B	$935.42M	$908.13M	$914.81M	$793.07M	$775.95M	$637.55M	$602.16M	$584.7M	$585.83M	$526.33M	$474.4M	$415.1M	$363.49M
Operating Income	+18.6%	+15.9%	+16.0%	—	—	$1.89B	$1.69B	$1.32B	$1.13B	$1B	$903.68M	$809.66M	$579.26M	$541.83M	$425.8M	$428.95M	$409.24M	$405.09M	$354.82M	$294.41M	$266.92M	$240.38M	$190.31M
Operating Margin	—	—	—	—	—	33.37%	32.75%	28.17%	26.8%	27.96%	28.27%	27.38%	22.22%	23.15%	20.6%	23.33%	24.38%	26.05%	23.43%	21.51%	21.47%	22.01%	20.67%
EBITDA	+17.2%	+14.5%	+15.0%	—	—	$2.09B	$1.88B	$1.5B	$1.3B	$1.16B	$1.06B	$964.51M	$730.06M	$661.79M	$537.96M	$515.8M	$482.29M	$478.54M	$433.1M	$380.26M	$337.54M	$301.95M	$244.27M
Interest Expense	-5.4%	+16.4%	+29.9%	—	$22.42M	—	—	—	—	—	$23.99M	$40.38M	$36.16M	$28.36M	$28.24M	$11.21M	$5.78M	$6.13M	$6.39M	$4.79M	$1.76M	$2.67M	—
Interest Income	-71.9%	-53.6%	-35.2%	—	—	—	—	—	—	—	$362K	$1.02M	$2.3M	$16.38M	$17.09M	$16.86M	$26.21M	$31.24M	$38.87M	$33.87M	$27.8M	$16.7M	$10.21M
Other Non-Operating Income	—	—	+11.9%	—	—	$32.7M	-$7.8M	-$55.1M	-$30.21M	-$39.8M	-$20.02M	-$76.57M	-$60.42M	-$20.52M	-$7.06M	$10.61M	$26.68M	$25.99M	$30.3M	$37.54M	$36.78M	$20.21M	$11.37M
Equity in Earnings of Unconsolidated Entities	—	—	—	—	—	$6.96M	$3.64M	-$1.85M	-$7.27M	-$8.49M	-$11.21M	-$25.06M	-$15.83M	—	—	—	—	—	—	—	—	—	—
Pretax Income	+20.3%	+16.8%	+15.9%	—	—	$1.92B	$1.68B	$1.26B	$1.1B	$960.48M	$883.66M	$733.09M	$518.85M	$521.31M	$418.74M	$439.57M	$435.92M	$431.08M	$385.12M	$331.95M	$303.71M	$260.59M	$201.68M
Income Tax	+24.7%	-0.6%	+16.3%	—	—	$396.12M	$276.84M	$243.85M	$204.11M	$181.05M	$409.16M	$111.41M	$114.26M	$205.72M	$76.46M	$87.16M	$83.03M	$85.81M	$77.99M	$77.1M	$76.72M	$70.5M	$55.24M
Net Income	+19.3%	+26.3%	+15.8%	—	—	$1.52B	$1.4B	$1.02B	$897.56M	$779.44M	$474.51M	$621.67M	$404.59M	$315.59M	$342.28M	$352.41M	$352.89M	$345.27M	$307.13M	$254.85M	$226.99M	$190.09M	$146.45M
Net Margin	—	—	—	—	—	26.94%	27.22%	21.79%	21.25%	21.78%	14.84%	21.02%	15.52%	13.49%	16.56%	19.17%	21.02%	22.2%	20.28%	18.62%	18.26%	17.4%	15.91%
Comprehensive Income	+17.4%	+21.8%	+17.5%	—	—	$1.52B	$1.58B	$1.04B	$937.78M	$660.18M	$565M	$590.7M	$375.91M	$280.32M	$375.88M	$303.27M	$27.81M	$404.74M	$162.77M	$166.87M	$465.04M	$86.38M	—
EPS (Basic) USD/shares	+19.6%	+26.2%	+15.4%	—	—	$10.47	$9.55	$6.94	$6.12	$5.34	$3.27	$4.31	$2.83	$2.21	$2.42	$2.51	$2.51	$2.44	$2.15	$1.75	$1.49	$1.26	$0.97
EPS (Diluted) USD/shares	+19.6%	+26.3%	+15.4%	—	—	$10.43	$9.51	$6.92	$6.09	$5.30	$3.24	$4.27	$2.80	$2.19	$2.40	$2.49	$2.47	$2.39	$2.10	$1.71	$1.44	$1.23	$0.95
Shares Outstanding (Basic Avg) shares	-0.3%	0.0%	+0.4%	—	—	145.52M	146.72M	147.02M	146.77M	146.07M	145.31M	144.34M	143.11M	142.76M	141.36M	140.24M	140.47M	141.47M	142.95M	145.9M	152.47M	150.91M	151.26M
Shares Outstanding (Diluted Avg) shares	-0.3%	-0.1%	+0.3%	—	—	146.05M	147.34M	147.55M	147.46M	147.04M	146.45M	145.65M	144.48M	143.99M	142.45M	141.67M	142.69M	144.36M	146.41M	149.32M	157.2M	155.1M	154.23M

Italic rows are computed from reported lines — open a row's info icon for its formula. Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing. TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative. (G): the company's own guidance — a (G) column is a guided period not yet reported; a G marker shows how the reported figure landed against the guided range. Non-GAAP-basis guidance (*) is shown as stated and never judged against GAAP actuals.

Capital Returned to Shareholders

Cash spent on share repurchases and dividends per fiscal year, as reported on the cash-flow statement. Across FY2009–FY2026: $2.63B in buybacks, $3.06B in dividends.

Price & Valuation

Multiples computed on the strict TTM/EV methodology — today's snapshot against peers, and each ratio recomputed as of past filing dates.

Valuation

EV/Revenue

5.99×

Peer median 2.45×

EV/EBIT

17.95×

Peer median 32.54×

P/E (TTM)

23.04×

Peer median 42.78×

Peer medians compare against the 16 similar-size Medical Instruments & Supplies companies (of 45 listed).

Valuation over time computed as of each quarter's filing date

Revenue Breakdown

Annual revenue as the company disaggregates it in its own XBRL filings. Years a component wasn't reported show a dash.

Share mode is each component's slice of the reported components that year — issuers rarely tag every revenue dollar, so slices need not sum to total revenue.

By Segment (USD)

Component	FY2026	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020	FY2019
Sleep and Breathing Health	$4,977,630,000	$4,504,890,000	$4,101,172,000	$3,725,017,000	—	—	—	—
Residential Care Software	$675,813,000	$641,437,000	$584,125,000	$497,976,000	—	—	—	—
Devices and Masks	—	—	—	—	—	$2,823,235,000	$2,602,381,000	$2,330,783,000
Sleep and Respiratory	—	—	—	—	$3,177,298,000	—	—	—
Software as a Service	—	—	—	—	$400,829,000	$373,590,000	—	—
Software as Service Before Deferred Revenue Adjustment	—	—	—	—	—	—	—	$281,137,000
Software as Service	—	—	—	—	—	—	$354,632,000	$275,789,000

By Geography (USD)

Component	FY2026	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020	FY2019
United States	$3,562,024,000	$3,285,581,000	$2,980,053,000	$2,719,923,000	$2,249,381,000	$1,962,721,000	$1,828,575,000	$1,588,655,000
Non Us	$2,091,419,000	$1,860,746,000	$1,705,244,000	—	—	—	—	—
Rest of World	—	—	—	$1,503,070,000	$1,328,746,000	$1,234,104,000	$1,128,438,000	$1,017,917,000
U.S. Canada and Latin America	—	—	—	—	$2,382,636,000	$2,078,703,000	$1,926,959,000	$1,696,285,000

By Product & Service (USD)

Component	FY2026	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020	FY2019
Sleep and Breathing Health	$4,977,630,000	$4,504,890,000	$4,101,172,000	$3,725,017,000	—	—	—	—
Residential Care Software	$675,813,000	$641,437,000	$584,125,000	$497,976,000	—	—	—	—
Sleep and Respiratory	—	—	—	—	$3,177,298,000	$2,823,235,000	$2,602,381,000	$2,330,783,000
Software as a Service	—	—	—	—	$400,829,000	$373,590,000	—	—
Software as Service	—	—	—	—	—	—	$354,632,000	$275,789,000

Segment Operating Income

Annual operating income by business segment, as tagged in the company's own XBRL filings. Segments need not sum to the consolidated figure — corporate costs and eliminations are typically unallocated.

By Segment (USD)

Component	FY2026	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020	FY2019
Sleep and Breathing Health	$2,204,498,000	$1,964,385,000	$1,681,354,000	$1,447,120,000	—	—	—	—
Residential Care Software	$217,731,000	$205,000,000	$154,450,000	$115,655,000	—	—	—	—
Devices and Masks	—	—	—	$1,502,475,000	$1,311,559,000	$1,170,305,000	$934,697,000	$766,068,000
Sleep and Respiratory	—	—	$1,681,354,000	$1,447,120,000	$1,279,591,000	—	—	—
Software as a Service	—	—	$154,450,000	$115,655,000	$93,756,000	$92,357,000	—	—
Software as Service	—	—	—	—	$93,821,000	$93,037,000	$82,152,000	$74,886,000

Operating Margin by Segment (%)

Component	FY2026	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020	FY2019
Sleep and Breathing Health	44.3%	43.6%	41%	38.8%	—	—	—	—
Residential Care Software	32.2%	32%	26.4%	23.2%	—	—	—	—
Devices and Masks	—	—	—	—	—	41.5%	35.9%	32.9%
Sleep and Respiratory	—	—	—	—	40.3%	—	—	—
Software as a Service	—	—	—	—	23.4%	24.7%	—	—
Software as Service	—	—	—	—	—	—	23.2%	27.2%

Key facts CIK 943819 CUSIP 761152107 13F (30d) 601 filings 575 filers Visit website Investor relations